Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Exclusion Criteria

• •history of clinically significant and not stably controlled endocrine, gastrointestinal, cardiovascular, hematological, hepatic (excepting HCV infection), immunological, renal, respiratory, genitourinary, or major neurological abnormalities or disease
• •history of cancer other than adequately treated non-melanomatous skin carcinoma, malignancies which have been successfully treated ≥10 years prior with no recurrence, or cancer that is unlikely to sustain a recurrence for the duration of the trial
• •history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
• •positive for hepatitis B surface antigen or human immunodeficiency virus
• •had major surgery or lost 1 unit of blood within 4 weeks prior to screening
• •QTc interval ≥470 msec (males) or ≥480 msec (females)
• •received prior treatment with other HCV inhibitors
• •clinical or laboratory evidence of decompensated liver disease